<DOC>
	<DOC>NCT00344110</DOC>
	<brief_summary>Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension</brief_summary>
	<brief_title>Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Age: 20 75 years old Gender: Male or female Status: Outpatients Mild to moderate essential hypertension Pregnant women, lactating mothers, women suspected of being pregnant, or women who wish to be pregnant Patients with msSBP &gt;==180 mmHg and/or msDBP &gt;=110 mmHg at Visit 1, 2 or 3 Patients with or suspected of having secondary hypertension (due to aortic coarctation, primary aldosteronism, etc.) Patients suspected of having malignant hypertension Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypertension, aliskiren, blood pressure, renin</keyword>
</DOC>